Introduction {#sec1-0956462419898612}
============

*Chlamydia trachomatis* (CT), *Neisseria gonorrhoeae* (NG) and *Trichomonas vaginalis* (TV) infections are important causes of morbidity among human immunodeficiency virus (HIV)-infected pregnant women and are associated with adverse pregnancy and birth outcomes^[@bibr1-0956462419898612],[@bibr2-0956462419898612]^; CT and NG infections have been shown to increase the risk of mother-to-child transmission of HIV infection.^[@bibr1-0956462419898612],[@bibr2-0956462419898612]^ Additionally, mothers may transmit untreated sexually transmitted infections (STIs) to a newborn at delivery, resulting in nasopharyngeal and/or conjunctival colonization which may progress to pneumonia and/or conjunctivitis.^[@bibr3-0956462419898612]^ Consequently, routine screening and treatment of STIs during pregnancy may decrease the risk of maternal transmission of HIV infection and infectious complications in infants.^[@bibr3-0956462419898612],[@bibr4-0956462419898612]^

In South Africa, like other resource limited settings, syndromic management of STIs in pregnancy is the current standard of care.^[@bibr5-0956462419898612]^ In syndromic STI management, clinicians treat patients based on defined symptoms, without an etiologic diagnosis. Given that most STIs are asymptomatic, syndromic management leaves a significant number of infections undiagnosed and untreated.^[@bibr6-0956462419898612],[@bibr7-0956462419898612]^ The adoption of new point-of-care diagnostic tests, which have been found to be highly acceptable and feasible, offers a more accurate method to detect and treat patients with CT, NG or TV infection.^[@bibr8-0956462419898612]^

Though CT, NG and TV infections are curable, several studies have reported persistent positivity after appropriate therapy.^[@bibr9-0956462419898612],[@bibr10-0956462419898612]^ Persistent positivity may be due to treatment failure, slow clearance of detectable CT, NG or TV nucleic acids, or re-infection.^[@bibr11-0956462419898612],[@bibr12-0956462419898612]^ However, few studies have sought to describe treatment outcomes for CT, NG and TV among HIV-infected pregnant women and predictors of persistent positivity.^[@bibr10-0956462419898612],[@bibr13-0956462419898612]^ To that end, we determined the frequency and predictors of persistent positive CT, NG and TV test results among HIV-infected pregnant women in Tshwane District, South Africa.

Methods {#sec2-0956462419898612}
=======

Study design {#sec3-0956462419898612}
------------

This is a sub-analysis of a larger cohort study of HIV-infected pregnant women which aimed to determine the acceptability and feasibility of integrating point-of-care molecular diagnostic testing for CT, NG and TV infections into antenatal care services.^[@bibr7-0956462419898612],[@bibr14-0956462419898612]^ Briefly, we incorporated same-day point-of-care diagnostic testing and treatment for urogenital CT, NG and TV infections into routine antenatal care provided to HIV-infected pregnant women.^[@bibr14-0956462419898612]^ We found antenatal STI screening to be highly acceptable to women and feasible. Participants who tested positive for CT, NG and/or TV during their antenatal care visit were treated and invited for repeat testing 21 days later. Eligibility criteria included: (1) enrolment during a participant's first antenatal care visit, (2) age ≥18 years, (3) currently pregnant and (4) estimated gestational age \<34 weeks. Using audio computer-assisted self-interview (ACASI) technology, study nurses and research assistants collected socio-demographic, self-reported genitourinary symptoms (e.g. abnormal vaginal discharge or bleeding or pain during intercourse or dysuria), mental health and sexual behaviour data. Study staff abstracted clinical data from participant's antenatal medical records.

Specimen collection, testing and management {#sec4-0956462419898612}
-------------------------------------------

Participants self-collected vaginal swab specimens using Xpert® CT/NG Vaginal/Endocervical Specimen Collection kits (Cepheid, Sunnyvale, California, USA) as previously described.^[@bibr14-0956462419898612]^ Trained staff at each clinic tested swabs for CT, NG and TV per the manufacturer's instructions (Xpert® CT/NG and Xpert® TV assays, Cepheid, Sunnyvale, California, USA). The Xpert® assays have greater than 99% sensitivity and specificity for the organisms tested.^[@bibr15-0956462419898612],[@bibr16-0956462419898612]^ Study nurses gave participants who tested positive for CT, NG and/or TV infection treatment per South African guidelines.^[@bibr5-0956462419898612]^ Participants with CT infection were treated with a 1 g oral stat dose of azithromycin. Those with NG infection were treated with a 250 mg intramuscular injection of ceftriaxone in addition to a 1 g oral dose of azithromycin. Those with TV infection were treated with oral metronidazole 400 mg twice daily for seven days. Study nurses directly observed treatment for CT and NG infection. Nurses gave TV treatment to participants to take at home. Nurses counselled participants with CT, NG or TV infection on safer sex practices and gave women the option to either take home (1) a partner referral letter for treatment or (2) a pill packet with the relevant medications for their sex partner(s). For cases of gonorrhoea, the partner pill packet included tablets of cefixime 400 mg and azithromycin 1 g.

Test-of-cure visits {#sec5-0956462419898612}
-------------------

Staff asked participants who tested positive for CT, NG and/or TV infection to return to the clinic 21 days after treatment initiation for repeat testing. Staff used a structured questionnaire to collect data from participants regarding disclosure of STI diagnosis and sexual behaviour between time-of-diagnosis and the test-of-cure visit. Staff provided re-treatment and repeat testing until the repeat test(s) were negative or a birth outcome was documented.

Data analysis {#sec6-0956462419898612}
-------------

We categorized as 'persistently positive' those participants who tested positive at a repeat visit for the same organism(s) for which treatment was previously provided. We summarized categorical variables using percentages and included the 95% confidence intervals (CIs) as appropriate. We used Chi square or Fisher's exact test to determine statistical significance of differences in categorical variables between individuals with positive and negative test-of-cure results. A P-value \<0.05 was considered statistically significant. We used multivariate Poisson regression analysis to calculate adjusted-prevalence ratios (aPRs) and identify determinants of positive CT, NG and TV results at test-of-cure. Any variable associated (P \< 0.20, univariate analysis) with a positive CT, and TV result at the repeat visit was included in the multivariate model; analysis for each organism was conducted separately. Maternal and gestational ages at enrolment (trimester) were included, a priori, in the multivariate models. Additionally, we assessed whether pre-treatment PCR cycle threshold values -- a measure of organism load -- were predictive of persistent test positivity.

Ethical considerations {#sec7-0956462419898612}
----------------------

Informed consent was obtained from all participants. Facility managers and the Tshwane District Department of Health Research Committee provided permission to conduct this study at selected antenatal care clinics. Ethical approval and oversight were provided by the Institutional Review Board of the University of Pretoria, Faculty of Health Sciences, Research Ethics Committee (reference number: 401/2015) and the University of California Los Angeles (reference number: 15-001351). The committees agreed with the provision of patient-delivered partner therapy.

Results {#sec8-0956462419898612}
=======

Between 1 June 2016 and 29 September 2017, we enrolled 430 participants at three primary healthcare facilities in Tshwane District, South Africa. Three participants were subsequently determined to have pseudo-pregnancies, and thus ineligible for the study. Consequently, 427 HIV-infected pregnant women were included in the final analysis.

All 427 participants were tested for CT, NG and TV at their first antenatal care visit, of which 172 (40.3%) tested positive for CT, NG and/or TV; CT = 126 (29.5%), NG = 24 (5.6%) and TV = 86 (20.1%) ([Table 1](#table1-0956462419898612){ref-type="table"}). Among those with a positive test result, 171 (99.4%) received treatment; one participant had received syndromic STI treatment six days prior to enrolment and was not provided additional treatment.

###### 

Count and proportion of sexually transmitted infections among HIV-infected pregnant women attending their first antenatal care visit, Tshwane District, South Africa.

![](10.1177_0956462419898612-table1)

                       N = 427                 
  -------------------- --------- ------ ------ ------
  Any STI (CT/NG/TV)   172       40.3   35.7   45.0
  CT infection         126       29.5   25.4   34.0
  NG infection         24        5.6    3.8    8.3
  TV infection         86        20.1   16.6   24.2

CT: *Chlamydia trachomatis*; NG: *Neisseria gonorrhoeae*; STI: sexually transmitted infection; TV: *Trichomonas vaginalis*.

Among those with a positive STI test result, 136 (79.1%) returned for test-of-cure. Of 126 individuals initially treated for CT, 102 (81.0%) returned for test-of-cure, of which 27 (26.5%) tested positive. Among the 24 individuals treated for NG at their first visit, 16 (66.7%) returned for test-of-cure, of whom one (6.3%) tested positive. Among 86 individuals initially treated for TV, 66 (76.7%) returned for a test-of-cure, of whom 11 (16.7%) tested positive ([Table 2](#table2-0956462419898612){ref-type="table"}).

###### 

Sexually transmitted infection positivity at repeat test-of-cure visits among human immunodeficiency virus-infected pregnant women, Pretoria, South Africa.

![](10.1177_0956462419898612-table2)

                                 First test-of-cure (ToC1)   Second test-of-cure (ToC2)   Third test-of-cure (ToC3)                    
  ------------------------------ --------------------------- ---------------------------- --------------------------- ------------ --- -----------
  Any CT, NG or TV at baseline   136                         36 (26.5%)                   29                          14 (48.3%)   9   7 (77.8%)
  CT positive at baseline        102                         27 (26.5%)                   22                          10 (45.5%)   5   3 (60.0%)
  NG positive at baseline        16                          1 (6.3%)                     1                           0            0   0
  TV positive at baseline        66                          11 (16.7%)                   9                           5 (55.6%)    4   4 (100%)

CT: *Chlamydia trachomatis*; NG: *Neisseria gonorrhoeae*; TV: *Trichomonas vaginalis*.

Of 136 participants returning for the first test-of-cure, 133 (97.8%) completed a post-treatment interview. Of those, 122 (91.7%) reported they disclosed their STI test results to their partner(s) ([Table 3](#table3-0956462419898612){ref-type="table"}). Among those 122 participants, 12 (9.8%) reported that their partner sought medical care, 67 (54.9%) reported that their partner accepted the partner treatment pill packet, 30 (24.6%) reported their partner(s) did not seek medical care, and 13 (10.7%) were unaware whether their partner had sought care. Of the 75 individuals (67.6%; 75/111) who reported engaging in sexual intercourse following their initial STI diagnosis, 42 (56.6%) said they always used condoms and 20 (26.7%) said that they never used condoms ([Table 3](#table3-0956462419898612){ref-type="table"}).

###### 

Interview responses on treatment disclosure and sexual activity among human immunodeficiency virus-infected pregnant women, Pretoria, South Africa.

![](10.1177_0956462419898612-table3)

  Test-of-cure interview response                              n     \%
  ------------------------------------------------------------ ----- ------
  Disclosed STI diagnosis to sexual partner(s)                       
   No                                                          11    8.3
   Yes                                                         122   91.7
  Time taken to disclose results to partner(s)                       
   Within 24 h                                                 105   86.1
   After 24 h                                                  17    13.9
  Partner sought medical care after being informed of result         
   No                                                          30    24.6
   Yes                                                         12    9.8
   No, but accept expedited  partner treatment                 67    54.9
   Don't know                                                  13    10.7
  Sexual intercourse since STI diagnosis                             
   No                                                          36    32.4
   Yes                                                         75    67.6
  Sexual partner since STI diagnosis                                 
   Regular partner                                             74    98.7
   Other partner                                               1     1.3
  Condom use since STI diagnosis                                     
   All the time                                                42    56.6
   Sometimes                                                   13    17.3
   Never                                                       20    26.7

STI: sexually transmitted infection.

Among participants treated for CT infection at their first antenatal care visit, those who reported having more than one sex partner in the preceding 12 months were more likely to have a persistent positive test compared to those who reported having only one sex partner (52.6% versus 20.7%; aPR = 3.03, 95% CI: 1.44--6.37). Furthermore, persistent CT positive test results were higher among participants diagnosed with HIV infection during their first antenatal care visit compared to those with a known HIV infection status and on antiretroviral therapy (ART) (40.0% versus 9.3%; aPR = 3.97, 95% CI: 1.09--14.43).

Among individuals treated for TV at their first antenatal care visit, those who did not know if their partner(s) sought treatment had a higher probability of having a persistent positive TV test result compared to women whose partner(s) accepted expedited partner treatment (42.9% versus 12.1%; aPR = 12.6, 95% CI: 2.16--73.5). Moreover, participants diagnosed with HIV infection prior to the first visit but not currently taking ART were more likely to have persistent TV positivity compared to those who were on ART (25.0% versus 9.7%; aPR = 4.14; 95% CI: 1.25--13.79) ([Table 4](#table4-0956462419898612){ref-type="table"}). Finally, participants who had pre-treatment PCR cycle threshold values consistent with a higher burden of infection (Ct value = ≤29) had a higher frequency of both CT and TV persistent positivity compared to those with a lower burden of infection, however these findings were not significant ([Table 4](#table4-0956462419898612){ref-type="table"}).

###### 

Associations of study participant characteristics and test-of-cure results among human immunodeficiency virus-infected pregnant women, Pretoria, South Africa.

![](10.1177_0956462419898612-table4)

  Characteristic                                               CT   TV                                                                                                                                                     
  ------------------------------------------------------------ ---- ---- ------ ------ ------ ------- ------- ---------------------- ------- ---- ---- ------ ------ ------ ------- ------- ---------------------- ------- --
                                                                                                                                                                                                                           
  Age group                                                                                                                                                                                                                
   \<25 years                                                  21   6    28.6   1.10   0.51   2.39    0.806                                  14   4    28.6   2.12   0.72   6.29    0.174                                  
   25--35 years                                                63   18   28.6   1.24   0.62   2.49    0.548                                  41   5    12.2   0.51   0.17   1.51    0.222                                  
   \>35 years                                                  18   3    16.7   0.58   0.20   1.74    0.333                                  11   2    18.2   1.11   0.27   4.50    0.883                                  
  Gestational age                                                                                                                                                                                                          
   1st Trimester (1--12 weeks)                                 22   3    13.6   0.45   0.15   1.38    0.163                                  12   1    8.3    0.45   0.06   3.24    0.282                                  
   2nd Trimester (13--27 weeks)                                67   22   32.8   2.30   0.95   5.57    0.065                                  45   8    17.8   1.24   0.36   4.26    0.728                                  
   3rd Trimester (28--34 weeks)                                13   2    15.4   0.55   0.15   2.06    0.373                                  9    2    22.2   1.41   0.36   5.55    0.625                                  
  Gravidity                                                                                                                                                                                                                
   1                                                           13   3    23.1   0.86   0.30   2.46    0.772                                  7    1    14.3   0.84   0.12   5.72    0.861                                  
   2                                                           31   14   45.2   2.47   1.31   4.63    0.005                                  23   4    17.4   1.07   0.35   3.30    0.909                                  
   3                                                           29   2    6.9    0.20   0.05   0.80    0.023                                  20   4    20.0   1.31   0.43   4.02    0.632                                  
   \>3                                                         29   8    27.6   1.06   0.52   2.15    0.872                                  16   2    12.5   0.69   0.17   2.92    0.619                                  
  Last known CD4 T cell count (cells/µl)                                                                                                                                                                                   
    \<200                                                      11   3    27.3   1.28   0.43   3.79    0.656                                  5    2    40.0   2.80   0.75   10.46   0.126                                  
    200--349                                                   18   2    11.1   0.43   0.11   1.72    0.233                                  7    0    0.0                                                                 
    350--499                                                   20   8    40.0   2.60   1.12   6.02    0.026                                  12   3    25.0   1.75   0.48   6.33    0.394                                  
    \>500                                                      23   3    13.0   0.49   0.15   1.57    0.231                                  23   3    13.0   0.63   0.17   2.36    0.489                                  
  Last known HIV viral load                                                                                                                                                                                                
    Detectable                                                 33   12   36.4   Ref                                                          18   6    33.3   Ref                                                          
    Undetectable                                               25   6    24.0   0.66   0.29   1.53    0.331                                  25   2    8.0    0.24   0.05   1.07    0.062                                  
  Knowledge of HIV status at first ANC                                                                                                                                                                                     
    Known HIV on ART                                           43   4    9.3    Ref                                                          31   3    9.7    Ref                                                          
    Known HIV not on ART                                       14   5    35.7   3.84   1.19   12.42   0.025                                  12   3    25.0   2.58   0.60   11.19   0.205   4.14 (1.25*--*13.79)   0.020   
    Diagnosed at ANC                                           45   18   40.0   4.30   1.57   11.74   0.004   3.97 (1.09*--*14.43)   0.036   23   5    21.7   2.25   0.59   8.54    0.235                                  
  Partner HIV status                                                                                                                                                                                                       
   Known                                                       32   4    12.5   Ref                                                          31   4    12.9                                                                
   Unknown                                                     55   19   34.5   2.76   1.02   7.45    0.045                                  27   5    18.5   1.44   0.42   4.86    0.562                                  
  Depression (first ANC visit)                                                                                                                                                                                             
    No depression (PHQ \<10)                                   93   25   26.9   Ref                                                          59   10   16.9   Ref                                                          
    Depression (PHQ  ≥10)                                      8    2    25.0   0.93   0.27   3.25    0.910                                  6    1    16.7   0.98   0.15   6.51    0.986                                  
  STI-associated symptoms (first ANC visit)                                                                                                                                                                                
    Asymptomatic                                               79   22   27.8   Ref                                                          49   9    18.4   Ref                                                          
    Symptomatic                                                23   5    21.7   0.78   0.33   1.84    0.571                                  17   2    11.8   0.64   0.15   2.70    0.544                                  
  STI-associated symptoms (test-of-cure visit)                                                                                                                                                                             
    Asymptomatic                                               88   24   27.3   Ref                                                          55   8    14.5   Ref                                                          
    Symptomatic                                                12   2    16.7   0.61   0.16   2.28    0.464                                  10   3    30.0   2.06   0.65   6.53    0.218                                  
  Disclosed STI diagnosis to sexual partner(s)                                                                                                                                                                             
    No                                                         4    2    50.0   Ref                                                          7    2    28.6   Ref                                                          
    Yes                                                        96   24   25.0   0.50   0.18   1.42    0.193                                  58   9    15.5   0.54   0.14   2.05    0.367                                  
  Time taken to disclose results to partner(s)                                                                                                                                                                             
    After 24 h                                                 14   5    35.7   Ref                                                          5    1    20.0   Ref                                                          
    Within 24 h                                                82   19   23.2   0.65   0.29   1.46    0.295                                  53   8    15.1   0.75   0.11   4.96    0.769                                  
  Partner sought medical care after being informed of result                                                                                                                                                               
    No                                                         23   6    26.1   1.06   0.48   2.36    0.890                                  15   2    13.3   0.82   0.19   3.56    0.790                                  
    Yes                                                        10   1    10.0   0.37   0.06   2.50    0.311                                  3    0    0.0                                                                 
    No, but accepted expedited partner treatment               55   14   25.5   1.04   0.51   2.12    0.906                                  33   4    12.1   0.61   0.18   2.05    0.420                                  
    Don't know                                                 8    3    37.5   1.57   0.59   4.16    0.363                                  7    3    42.9   3.64   1.16   11.49   0.027   12.6 (2.16*--*73.5)    0.005   
  Sexual intercourse since STI diagnosis                                                                                                                                                                                   
    No                                                         26   7    26.9   Ref                                                          21   6    28.6   Ref                                                          
    Yes                                                        59   15   25.4   0.94   0.44   2.05    0.885                                  36   5    13.9   0.49   0.17   1.41    0.185                                  
  Condom use since STI diagnosis                                                                                                                                                                                           
    All the time                                               35   12   34.3   2.74   0.86   8.78    0.089                                  20   2    10.0   0.53   0.10   2.88    0.465                                  
    Sometimes                                                  10   0    0.0    --                                                           4    0    0.0                                                                 
    Never                                                      14   3    21.4   0.80   0.26   2.47    0.703                                  12   3    25.0   3.00   0.56   15.98   0.198                                  
  More than one sex partner in the past 12 months                                                                                                                                                                          
    No                                                         82   17   20.7   Ref                                                          49   7    14.3   Ref                                                          
    Yes                                                        19   10   52.6   2.54   1.39   4.64    0.002   3.03 (1.44*--*6.37)    0.003   16   4    25.0   1.75   0.58   5.26    0.319                                  
  Pre-treatment cycle threshold (Ct) value                                                                                                                                                                                 
    Strong positive (≤29)                                      40   13   32.5                                                                40   10   25.0                                                                
    Moderate positive (\>29≥37)                                37   8    21.6   0.67   0.31   1.426   0.295                                  12   0    0.0                                                                 
    Weak positive (\>37)                                       25   6    24.0   0.74   0.32   1.70    0.475                                  14   1    7.1    0.29   0.04   2.07    0.215                                  

ANC: antenatal care; ART: antiretroviral therapy; CT: *Chlamydia trachomatis*; HIV: human immunodeficiency virus; NG: *Neisseria gonorrhoeae*; PHQ: Patient Health Questionnaire; STI: sexually transmitted infection; TV: *Trichomonas vaginalis*.

We could not assess determinants of persistent NG positivity due to the limited sample size.

Discussion {#sec9-0956462419898612}
==========

Our study investigated the frequency and predictors of persistent positive CT, NG and/or TV tests after locally recommended treatment in HIV-infected pregnant women. We found more than 25% of women returning for their test-of-cure visit had a persistent positive STI test. Among our participants, the frequency of persistent positive CT results following treatment (26.5%) was higher than previously reported in studies among pregnant women from the United States (15.4%) and Peru (14.0%).^[@bibr17-0956462419898612],[@bibr18-0956462419898612]^ In comparison, the 16.7% persistent TV positivity was only slightly higher than the 6--15% persistent TV positivity reported by others.^[@bibr19-0956462419898612]^

Although more than 90% of women in our study reported disclosing their STI diagnosis to sex partners, nearly a quarter reported that their sex partner(s) did not seek medical care, and another 10% were unaware if their sex partner(s) sought medical care. Lack of knowledge of whether their sex partner(s) received treatment was significantly associated with persistent TV positivity. Among those with persistent CT positivity, having more than one sex partner in the preceding 12 months was a significant risk factor. Together, these finding suggest that the elevated frequency of persistent TV and CT positivity may be due to increased risk of re-exposure/re-infection by sexual partners and sexual networks. Others have described possible reasons for persistent positivity including delayed clearance of non-viable microbial nucleic acids, treatment failure due to antimicrobial resistance and re-infection by sex partners.^[@bibr20-0956462419898612]^ Similarly, our results suggest that persistent CT and TV test positivity may be due to multiple factors.

We also report that HIV-infected women not on ART had a higher frequency of persistent TV positivity. That finding is in contrast to a Kenyan study which reported that HIV-infected women on nevirapine-based ART had a higher frequency of persistent TV infection after treatment compared to HIV-infected women not on ART.^[@bibr21-0956462419898612]^ In that study, a 2 g single dose of metronidazole had a lower success rate in TV-infected women who were on ART compared to those who were not on ART. Adamski et al.^[@bibr22-0956462419898612]^ corroborated those findings in a study of 226 HIV-infected women with TV on a variety of antiretroviral regimens. In that study, those on ART had a higher frequency of persistent TV positivity after treatment than those not on ART, with more treatment failures occurring among women receiving the 2 g single dose of metronidazole compared to a seven-day 500 mg twice daily regimen. The authors suggested that ART is a marker of some other biological factor that interferes with metronidazole treatment of TV infection. However, what this other biological factor(s) may be is unknown. Reasons for the discrepancy between our findings and those of previous studies are unknown. To elucidate the interaction between ART and metronidazole investigators should conduct pharmacokinetic studies.

Similar to women with persistent TV positivity, we found that women not on ART were more likely to also be persistently positive for CT. Whether that observation is due to HIV-related immune dysregulation in women with untreated HIV infection or due to drug--drug interactions is unknown. Similar to metronidazole, the exact mechanism by which ART may alter azithromycin efficacy is also unclear. Efavirenz, emtricitabine and tenofovir-diphosphate, the three drugs which make up South Africa's first line fixed dose combination ART, do not seem to have significant interactions with azithromycin.^[@bibr23-0956462419898612]^ A slight increase in the maximum serum concentration of azithromycin has been reported when used in combination with efavirenz.^[@bibr24-0956462419898612]^ Though antiretroviral medications are known to have an effect on the constitution of the gut microbiome,^[@bibr25-0956462419898612]^ evidence suggests that antiretroviral medications on their own do not lead to reconstitution of the gut microbiome from dysbiosis to a healthy state similar to HIV-uninfected individuals.^[@bibr26-0956462419898612]^ Further studies are needed to investigate the causal pathway between ART, immune dysregulation and STI treatment outcomes, as well as the role of the vaginal microbiome and STI clearance.

Some sexual behaviours and partner characteristics were also associated with persistent STI positivity in our study. In multivariate analysis, we found that women who reported more than one sex partner in the preceding 12 months were more likely to test persistently positive for CT compared to women who did not have multiple partners. That finding is consistent with prior studies that found higher rates of CT persistent positivity among women in multiple concurrent partnerships.^[@bibr27-0956462419898612],[@bibr28-0956462419898612]^ We also found that participants who were unsure whether their partner(s) sought STI treatment had a higher probability of persistent TV positivity compared to those who knew their partner sought treatment. That strongly suggests re-infection due to lack of partner treatment related to complex partner dynamics and poor communication which may influence the risk of acquiring repeat STIs.^[@bibr29-0956462419898612],[@bibr30-0956462419898612]^

Nucleic acid amplification tests to detect infections, similar to the one used in our study, cannot distinguish between nucleic acids from viable or non-viable organisms.^[@bibr31-0956462419898612]^ Cell culture has been used to assess whether detected DNA represents viable infectious microorganisms. When used in combination with high resolution molecular typing methods, cell culture may provide key information regarding persistent positivity. A limitation in our current study is the lack of culture and molecular typing data. However, we previously reported on a sub-study involving TV culture in a subset of women with persistent positive TV results.^[@bibr32-0956462419898612]^ In that study we found that 50% of participants with a positive test-of-cure results had viable organisms. That study also found that test-of-cure PCR cycle threshold value from test-of-cure specimens was predictive of *T. vaginalis* culture positivity, and thus viable infection.

In a study conducted among non-pregnant women in the Netherlands, Versteeg et al.^[@bibr33-0956462419898612]^ found that women with PCR cycle threshold values consistent with a higher burden of infection were more likely to be culture positive as well. Similarly, we found pre-treatment PCR cycle threshold values were predictive of persistent test positivity. However, those results were not statistically significant. Given that specimens were self-collected, variations in the amount of material collected on a swab for testing may not have been well standardized, and thus impacted cycle threshold values.

Social desirability response bias to survey questions on sexual behaviour, sexual history and alcohol use may also have contributed to study limitations. Specifically, the sensitivity of survey questions may have not been sufficient to capture behavioural factors associated with re-infection. We also did not ascertain from partners themselves their treatment exposure, a challenge not unique to our study.^[@bibr34-0956462419898612]^ Finally, we did not have specific measures other than self-report to confirm medication adherence with the multiday regimen for TV treatment. Consequently, we could not determine if adherence was associated with TV persistence.

Conclusions {#sec10-0956462419898612}
===========

We observed a high frequency of CT and TV persistent positivity after treatment among a cohort of HIV-infected pregnant women in South Africa. However, we could not conclusively distinguish between treatment failure, re-infection, or slow clearance of CT and TV nucleic acids following treatment. More than one recent sex partner and lack of knowledge of uptake of partner treatment were independent determinants of persistent positivity, indicating that persistent positivity may be due to re-infection by partners. This may be particularly important in settings where CT is hyperendemic. That highlights the need to improve safer sex counselling among HIV-infected pregnant women diagnosed with STIs and to determine optimal cost-effective strategies for repeat screening and partner treatment. Effective partner treatment programmes are needed to improve the effectiveness of STI screening and treatment programmes, especially during antenatal care. The relationship between ART, HIV-related immunosuppression and STI treatment outcomes needs to be explored further.
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